브랜드 제네릭 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Branded Generics Market size is expected to reach USD 518.86 Billion in 2034 from USD 304.78 Billion (2025) growing at a CAGR of 6.09% during 2026-2034.

The global branded generics market is experiencing strong growth due to the increasing demand for cost-effective yet reliable pharmaceutical products. Branded generics are off-patent drugs marketed under a brand name, offering quality assurance along with affordability. The rising prevalence of chronic diseases and the growing need to reduce healthcare costs are key factors driving market expansion. Additionally, increasing access to healthcare in emerging markets is boosting demand for branded generics.

Key growth drivers include patent expirations of major drugs and the growing focus on affordable healthcare solutions. Pharmaceutical companies are investing in branded generics to maintain market presence and expand their product portfolios. The increasing trust among consumers and healthcare providers in branded generics is also supporting market growth. Furthermore, government initiatives promoting the use of generic medicines are contributing to market expansion.

Looking ahead, the branded generics market is expected to grow significantly with expanding healthcare access and increasing demand for affordable treatments. Emerging markets are anticipated to offer substantial growth opportunities due to rising disposable incomes and healthcare awareness. Additionally, continuous innovation in drug formulations and marketing strategies will further strengthen the market position of branded generics globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-hypertensive
• Lipid Lowering Drugs
• Anti-depressants
• Anti-psychotics
• Anti-epileptics
• Others

By Application

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Gastrointestinal Diseases
• Dermatological Diseases
• Acute and Chronic Pain
• Others

By Route of Administration

• Topical
• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, Lupin, Sanofi, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Endo International plc, GlaxoSmithKline plc, Pfizer Inc, Apotex Inc, Viatris Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BRANDED GENERICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Alkylating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antimetabolites Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-hypertensive Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Lipid Lowering Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Anti-depressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Anti-psychotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Anti-epileptics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BRANDED GENERICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Gastrointestinal Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Dermatological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Acute and Chronic Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BRANDED GENERICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BRANDED GENERICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Application
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Application
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Application
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Application
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Application
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BRANDED GENERICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Teva Pharmaceutical Industries Ltd
  • 10.2.2 Lupin
  • 10.2.3 Sanofi
  • 10.2.4 Sun Pharmaceutical Industries Ltd
  • 10.2.5 Dr. Reddy's Laboratories Ltd
  • 10.2.6 Endo International Plc
  • 10.2.7 GlaxoSmithKline Plc
  • 10.2.8 Pfizer Inc
  • 10.2.9 Apotex Inc
  • 10.2.10 Viatris Inc